Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLTP | P55058 | 8/20 | 0.61 |
| ▸ | TOP1 | P11387 | 1/20 | 0.58 |
| ▸ | RRM1 | P23921 | 2/20 | 0.55 |
| ▸ | RRM2B | Q7LG56 | 2/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Coh-29 SCHEMBL10036527 | 1.00 | PLTP (0.61) | PLTPTOP1RRM1RRM2BADORA2A | |
| Coh-29 SCHEMBL31436912 | 1.00 | PLTP (0.61) | PLTPTOP1RRM1RRM2BADORA2A | |
| SCHEMBL12940263 | 0.94 | PLTP (0.59) | PLTPTOP1RRM1RRM2BADORA2A | |
| SCHEMBL10002075 | 0.81 | PLTP (0.86) | PLTPTOP1RRM1RRM2BSMN1; SMN2 | |
| SCHEMBL10002071 | 0.81 | PLTP (0.63) | PLTPTOP1RRM1RRM2BMAPT | |
| SCHEMBL235132 | 0.81 | ADORA2A (0.76) | ADORA2AADORA1SMN1; SMN2KMT2AHPGD | |
| SCHEMBL20343833 | 0.80 | PLTP (0.48) | PLTPTOP1RRM1RRM2BADORA2A | |
| SCHEMBL12802354 | 0.80 | L3MBTL1 (0.61) | ADORA1SMN1; SMN2KMT2AHPGDMAPT | |
| SCHEMBL2753880 | 0.80 | SMN1; SMN2 (0.59) | ADORA2AADORA1SMN1; SMN2KMT2AHPGD | |
| SCHEMBL2753294 | 0.79 | ADORA3 (0.74) | ADORA2AADORA1SMN1; SMN2KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12246017-B2 | Replication stress pathway agent compositions and methods for treating cancer | BOUNDLESS BIO, INC. (US) | 2025-03-11 | — | — | US | claimed |
| CN-117838687-A | Application of COH29 in preparation of medicine for improving sensitivity of prostate cancer to enzalutamide treatment | 中山大学孙逸仙纪念医院 | 2024-04-09 | — | — | CN | claimed |
| US-20230272485-A1 | REPLICATION STRESS PATHWAY AGENT COMPOSITIONS AND METHODS FOR TREATING CANCER | BOUNDLESS BIO, INC. | 2023-08-31 | — | — | US | claimed |
| US-20230248728-A1 | REPLICATION STRESS PATHWAY AGENT COMPOSITIONS AND METHODS FOR TREATING CANCER | BOUNDLESS BIO, INC. | 2023-08-10 | — | — | US | claimed |
| EP-3128842-B1 | TREATMENT OF BRCA1-DEFECTIVE CANCER OR RESISTANT CANCERS | HOPE CITY (US) | 2023-07-26 | — | — | EP | claimed |
| CN-116368243-A | Replication stress pathway agent compositions and methods for treating cancer | 无界生物公司 | 2023-06-30 | — | — | CN | claimed |
| EP-4196614-A1 | REPLICATION STRESS PATHWAY AGENT COMPOSITIONS AND METHODS FOR TREATING CANCER | Boundless Bio, Inc. (US) | 2023-06-21 | — | — | EP | claimed |
| CN-113082025-B | Application of dihydroxy benzamide derivative in preparation of SerC inhibitor and antituberculosis drug | 上海市肺科医院 | 2023-01-20 | — | — | CN | claimed |
| US-20260062760-A1 | METHODS OF TREATMENT AND DIAGNOSIS OF MULTIPLE MYELOMA PROGRESSION | MOREHOUSE SCHOOL OF MEDICINE (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260055473-A1 | METHODS OF TREATMENT AND DIAGNOSIS OF MULTIPLE MYELOMA PROGRESSION | MOREHOUSE SCHOOL OF MEDICINE (US) | 2026-02-26 | — | — | US | disclosed |
| US-12527790-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | BOUNDLESS BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4532486-A1 | PYRIDINE CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | Boundless Bio, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| US-20250092032-A1 | DEOXYCYTIDINE KINASE INHIBITORS | INSTITUT JEAN PAOLI & IRENE CALMETTES CENTRE REGIONAL DE LUTTE CONTRE LE CANCER (FR) | 2025-03-20 | — | — | US | disclosed |
| US-12246017-B2 | Replication stress pathway agent compositions and methods for treating cancer | BOUNDLESS BIO, INC. (US) | 2025-03-11 | — | — | US | disclosed |
| US-11547711-B2 | Replication stress pathway agent compositions and methods for treating cancer | BOUNDLESS BIO, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2022251502-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022221181-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CANCER | YALE UNIVERSITY (US) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022097142-A2 | METHODS OF PROGNOSING, DETERMINING TREATMENT COURSE AND TREATING MULTIPLE MYELOMA | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-05-12 | — | — | WO | disclosed |
| US-20220143022-A1 | REPLICATION STRESS PATHWAY AGENT COMPOSITIONS AND METHODS FOR TREATING CANCER | BOUNDLESS BIO, INC. | 2022-05-12 | — | — | US | disclosed |
| US-20220048863-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062760-A1 | METHODS OF TREATMENT AND DIAGNOSIS OF MULTIPLE MYELOMA PROGRESSION | HNRNPH3, HNRNPH1, UTRN | PLTP 3837/4885TOP1 4171/4885RRM1 1680/4885 |
| US-12527790-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | CHEK1, RAD1, CHEK2 | PLTP 4793/4885TOP1 74/4885RRM1 202/4885 |
| US-20220048863-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | DNA2, TOP2A, TOP2B | PLTP 3205/4885TOP1 6/4885RRM1 1351/4885 |
| US-20250092032-A1 | DEOXYCYTIDINE KINASE INHIBITORS | DCK, DTYMK, TYMP | PLTP 2865/4885TOP1 528/4885RRM1 1045/4885 |
| US-20260055473-A1 | METHODS OF TREATMENT AND DIAGNOSIS OF MULTIPLE MYELOMA PROGRESSION | HNRNPH3, MYCBP2, HNRNPH1 | PLTP 3809/4885TOP1 4129/4885RRM1 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.